首页|期刊导航|中医临床研究|基于网络药理学与分子对接探究右归饮加减方治疗骨髓增生异常综合征的作用机制

基于网络药理学与分子对接探究右归饮加减方治疗骨髓增生异常综合征的作用机制OA

Mechanism of modified Yougui Yin in treating myelodysplastic syndrome based on network pharmacology and molecular docking

中文摘要英文摘要

目的:采用网络药理学和分子对接技术探讨右归饮加减方治疗骨髓增生异常综合征的作用方式与分子机制.方法:通过中药系统药理学数据库与分析平台(TCMSP)等获取右归饮加减方的化学成分及预测其作用靶点.利用 GeneCards 数据库等检索骨髓增生异常综合征的相关靶点.使用韦恩图获取交集靶点,将交集靶点导入STRING 11.5数据库,用于构建右归饮加减方治疗骨髓增生异常综合征靶点的蛋白质-蛋白质相互作用网络,并借助 Cytoscape 3.9.1 软件筛选核心靶点.用 DAVID 基因功能注释分析工具对交集靶点进行京都基因与基因组百科全书(KEGG)通路及基因本体论(GO)功能富集分析.使用 Cytoscape 3.9.1 软件构建药物活性成分-靶点-通路相互作用网络,获取核心有效成分.利用 AutoDock、PyMOL 软件进行核心靶标分子对接.结果:筛选出右归饮加减方化学成分 72 个,药物靶点 293 个,骨髓增生异常综合征疾病靶点 1 486 个,药物-疾病交集靶点 136 个.槲皮素、1-羟基-3-甲氧基-9,10-蒽醌、木犀草素、金合欢素、7-O-甲基异微凸剑叶莎醇等是右归饮加减方的有效成分,主要涉及肿瘤蛋白 p53(tumor protein p53,TP53)、丝氨酸/苏氨酸蛋白激酶 1(Akt serine/threonine-protein kinase 1,AKT1)、热休克蛋白90α家族A类成员1(heat shock protein 90 alpha family class A member 1,HSP90AA1)、肿瘤坏死因子(tumor necrosis factor,TNF)和 JUN 原癌基因(Jun proto-oncogene,JUN)等靶点,参与调控磷脂酰肌醇 3 激酶(phosphoinositide 3-kinase,PI3K)/蛋白激酶 B(protein kinase B,Akt)信号通路、糖尿病并发症中的晚期糖基化终末产物(advanced glycation end product,AGE)-晚期糖基化终末产物受体(advanced glycation end product receptor,RAGE)信号通路和丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路等信号通路.结论:本研究在总体上预测了右归饮加减方治疗骨髓增生异常综合征的有效成分、作用靶点及调控通路,为后续的研究提供理论基础.

Objective:To investigate the mechanism of action and molecular targets of modified Yougui Yin(右归饮加减方)in the treatment of myelodysplastic syndrome(MDS)using network pharmacology and molecular docking.Methods:Chemical constituents of modified Yougui Yin and their predicted targets were retrieved from databases including the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).Disease targets associated with MDS were obtained from databases such as GeneCards.Common targets between the drug and the disease were identified using a Venn diagram.These common targets were imported into the STRING 11.5 database to construct a protein-protein interaction(PPI)network for modified Yougui Yin in MDS treatment.Core targets were screened using Cytoscape 3.9.1 software.Functional enrichment analyses,including gene ontology(GO)and Kyoto encyclopedia of genes and genomes(KEGG)pathway analyses,were performed on the common targets using the DAVID bioinformatics tool.A drug-active component-target-pathway interaction network was constructed with Cytoscape 3.9.1 to identify core active components.Molecular docking of core targets was performed using AutoDock and PyMOL software.Results:A total of 72 chemical components and 293 potential targets of modified Yougui Yin were identified,along with 1 486 MDS-related targets.Among them,136 overlapping targets were obtained.Key active components included quercetin,1-hydroxy-3-methoxy-9,10-anthraquinone,luteolin,acacetin and 7-O-methylisomucronulatol.Core targets involved tumor protein p53(TP53),Akt serine/threonine-protein kinase 1(AKT1),heat shock protein 90 alpha family class A member 1(HSP90AA1),tumor necrosis factor(TNF),and Jun proto-oncogene(JUN).Enriched pathways included the PI3K-Akt signaling pathway,AGE-RAGE signaling pathway in diabetic complications,and the MAPK signaling pathway.Conclusion:This study provides a comprehensive prediction of the active components,potential targets,and regulatory pathways involved in the treatment of MDS with modified Yougui Yin,offering a theoretical foundation for subsequent research.

刘海英;司文涛;李育林;唐旭东

山东中医药大学第一临床医学院,山东 济南,250355烟台市中医医院,山东 烟台,264013烟台市中医医院,山东 烟台,264013中国中医科学院西苑医院,北京,100091

医药卫生

网络药理学右归饮加减方骨髓增生异常综合征分子对接

Network pharmacologyModified Yougui YinMyelodysplastic syndromeMolecular docking

《中医临床研究》 2026 (18)

1-13,13

国家中医药管理局科技司共建科技项目(GZYKJSSD2023017)山东省中医药科技项目(2021M091)齐鲁中医药优势专科集群建设项目(肿瘤科)(鲁卫函202246号)烟台市科技计划项目(2023YD016).

10.3969/j.issn.1674-7860.2026.18.001

评论